At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 838 enrolled
Drug / intervention
AZD9668 +3 moredrug
Likely dose
AZD9668 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
In Brief
A Phase 2 clinical trial evaluating AZD9668 and AZD9668 Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 838 participants across 105 sites in 12 countries.
Detailed Summary
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesAustralia, Canada, Germany, Japan, Philippines, Poland, Russia, Slovakia, South Korea, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedJul 31, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.9 years ago
Interventions
AZD9668drug
2 x 30 mg oral tablets twice daily (bid) for 12 weeks
AZD9668drug
2 x 10 mg oral tablets twice daily (bid) for 12 weeks
AZD9668drug
2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
AZD9668 Placebodrug
2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks